A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4213-4218

  Tham, Lai San ^a,d   Wang, Lingzhi ^a   Soo, Ross A ^a   Lee, Soo Chin ^a   Lee, How Sung ^b   Yong, Wei Peng ^a   Goh, Boon Cher ^a   Holford, Nicholas H G ^c  

^a National University Hospital   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; CARBOPLATIN; DRUG METABOLITE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; KINETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 48249084994     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4754     Document Type: Article

References (32)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
2. Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21.
3. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs 2003;21:183-94.
4. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997;24:S7-2-S7-7.
5. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23:3-15.
6. Grunewald R, Abbruzzese JL. Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258-62.
7. Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990;50: 6823-6.
8. Toschi L, Finocchiaro G, Bartolini S, et al. Role of gemcitabine in cancer therapy. Future Oncol 2005;1:7-17.
9. Edelman MJ Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer. Lung Cancer Suppl 2002;2:S37-43.
10. Danson S, Middleton MR, O'Byme KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98:542-53.
11. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 2002;3:50-4.
12. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
13. Soo RA, Wang LZ. Tham LS, et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage nonsmall-cell lung cancer. Ann Oncol 2006;17:1128-33.
14. Xu XL. The biological foundation of the Gompertz model. Int J Biomed Comput 1987;20:35-9.
15. Bajzer Z, Marusic M, Vuk-Pavlovic S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math Comput Model 1996;23: 31-46.
16. Holford NHG, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A 1992;89:11466-70.
17. Jacqmin P, Snoeck E. van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007;34:57-85.
18. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64: 1094-101.
19. deVladar HP, Gonzalez JA. Dynamic response of cancer under the influence of immunological activity and therapy. J Theor Biol 2004;227:335-48.
20. Kozusko F, Bajzer Z. Combining Gompertzian growth and cell population dynamics. Math Biosci 2003;185:153-67.
21. Albano G, Giorno V. A stochastic model in tumor growth. J Theor Biol 2006;242:329-36.
22. Castro MA, Klamt F, Grieneisen VA, et al. Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines. Cell Prolif 2003;36:65-73.
23. Claret L, Girard P. Zuideveld KP, et al. A longitudinal model for tumor size measurements in clinical oncology studies [abstract 1004]. Abstr Annu Meet Population Approach Group in Europe 2006;Abstract 1004:15
24. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991:9:491-8
25. Heinnemann V, Hertel LW, Grindey GB, et al Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31
26. Tempero M, Plunkett W, Ruiz Van Haperen V. et al Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-8.
27. Shewach DS, Lawrence TS It's what's inside that counts. J Clin Oncol 2003;21:3383-4.
28. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-9.
29. Therasse P, Measuring the clinical response What does it mean? Eur J Cancer 2002;38:1817-23
30. James K, Eisenhauer E, Christian M, et al Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999: 91:523-8.
31. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179-81
32. Miller AB, Hoogstraten B. Staquet M, et al Reporting results of cancer treatment. Cancer 1981. 47:207-14.